WCLC 2025 - Posters & ePosters-EP.11.06 First-Line Immunotherapy for PD-L1 =50% Advanced NSCLC vs EGFR-TKIs in EGFR-Mutant NSCLC: A Retrospective Single-Center Study

EP.11.06 First-Line Immunotherapy for PD-L1 =50% Advanced NSCLC vs EGFR-TKIs in EGFR-Mutant NSCLC: A Retrospective Single-Center Study

Asset Subtitle

Shun Futamura

Meta Tag

Speaker Shun Futamura

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy